BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2003

View Archived Issues

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Adventrx Pharmaceuticals

Read More

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Avidex

Read More

Prous Science DailyDrugNews and LifeSci Channel announce highlights from Rodman & Renshaw Techvest

Read More

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Avant Immunotherapeutics

Read More

R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: BioCryst

Read More

Sleep-promoting effects of gaboxadol, a selective GABA-A receptor agonist, in rats

Read More

HCT-1026 and ibuprofen reduce resiniferatoxin-induced bladder hyperactivity in rats

Read More

Anandamide and oleamide increase food intake in rats

Read More

CB1 antagonists and their use reported by Sanofi-Synthelabo researchers

Read More

Kyowa Hakko and Millennium present new chemokine CXCR3 modulators

Read More

New cathepsin K inhibitors prepared and tested by GSK scientists

Read More

Novel cytokine production inhibitors covered by Boehringer Ingelheim patent

Read More

Axxima claims novel inhibitors of M. tuberculosis protein kinase PknG

Read More

New antidiabetic agent from plant origin identified by Indian researchers

Read More

Almirall Prodesfarma presents new muscarinic M3 antagonists in a recent patent

Read More

Novel 5-HT and/or dopamine receptor ligands discovered by Sepracor team

Read More

Access files OraDisc A NDA

Read More

Fast track designation for C31G vaginal gel

Read More

Boehringer and TeGenero partner for production of CD28-SuperMAB

Read More

deCODE acquires Bayer compound for heart attack prevention

Read More

New Zealand phase II trial for AVAC in pediatric atopic dermatitis

Read More

Genmab and ACE BioSciences identify first target in collaboration

Read More

MGI and Helsinn expand North American Aloxi agreement

Read More

MBI-594AN shows efficacy in phase IIb acne study

Read More

Thalidomide approved for multiple myeloma and ENL in Australia

Read More

Italian phase III trial for ADI in liver cancer

Read More

DES may facilitate repair of damaged nerve cells

Read More

Atherosclerosis regression with an apo A-I mimetic in acute coronary syndrome patients

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 18, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • GLP-1 capsule

    Maintenance, man: Lilly’s phase III weight trial hits goals

    BioWorld
    Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
  • Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

    AI drug developer Insilico to raise $292 million in Hong Kong IPO

    BioWorld
    Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing